Theradiag SA
PAR:ALTER

Watchlist Manager
Theradiag SA Logo
Theradiag SA
PAR:ALTER
Watchlist
Price: 1.26 EUR Market Closed
Market Cap: 16.4m EUR
Have any thoughts about
Theradiag SA?
Write Note

Theradiag SA
Investor Relations

Theradiag SA engages in the distribution, development and manufacturing of in vitro diagnostic and theranostics tests. The company is headquartered in Croissy-Beaubourg, Ile-De-France. The company went IPO on 2012-12-11. The firm develops and offers product panels for diagnosing autoimmune diseases, allergies, and infectious diseases. TheraDiags product offering consists of tests using a range of techniques (Elisa, rapid tests, immunofluorescence, Dot, immunochemical tests, molecular biology, etc.) as well as a range of automatic devices and solutions for high-speed diagnostics based on Luminexs Multiplex technology. The company has also developed a range of theranostic diagnostics commercialized under the Lisa-Tracker brand which provide monitoring of patients treated by anti-TNF monoclonal antibodies. TheraDiag is active in more than 30 countries, as an independent distributor.

Show more

Earnings Calls

No Earnings Calls Available

Management

Mr. Bertrand De Castelnau
Chief Exec. Officer
No Bio Available
Ms. Muriel Bardet
Chief Financial Officer
No Bio Available
Mr. Ermis Parussini
Exec. Director of Operations and R&D
No Bio Available
Mr. Roland Carbonnel
VP Marketing and Sales
No Bio Available

Contacts

Address
ILE-DE-FRANCE
Croissy-Beaubourg
14 Rue Ambroise Croizat
Contacts
+33164621012
www.theradiag.com